Keywords
Cancer
Abuse
Adverse Events
How to Cite
Abstract
Objective: To evaluate how the indiscriminate use of morphine affects end-stage cancer patients. Methods: Integrative review study, with a descriptive and qualitative approach, about the effects of indiscriminate use of morphine among patients with end-stage cancer, between 2013 and 2023. Results: Initially, applying criteria of language, year of publication and availability in full, 1,879 articles were considered, of which 1,521 were excluded because they were reviews, documents and books, resulting in 358 articles read in full, in which 14 met all the inclusion criteria. In summary, two studies bring positive aspects of prolonged morphine regarding the analgesic effects and minimal adverse events, however, 12 studies bring different approaches regarding the indiscriminate use of morphine, in order to demonstrate divergences regarding aspects of pain control, however, a better description as to the occurrence of adverse events (especially nausea, constipation and sleepiness), drug addiction/tolerance and risk of death associated with stroke, AEs, and sepsis. Conclusion: There is still literature divergence as to the contribution of morphine in pain reduction, although some authors point out its contribution, however, it is well reported that the indiscriminate use may reflect in problems of AEs level, tolerance and risks to death, therefore, it is necessary to discuss its prescription in order to promulgate an effective medical monitoring and control in administration.
Keywords: Morphine; Cancer; Abuse; Adverse Events.
References
Azhar A, Kim YJ, Haider A, Hui D, Balankari VR, Epner MC, Park M, Liu DD, Williams J, Frisbee-Hume SE, Allo JA & Bruera E. Response to Oral Immediate-Release Opioids for Breakthrough Pain in Patients with Advanced Cancer with Adequately Controlled Background Pain. Oncologist. 2019 ;24(1):125-131.
Bastos DF, Silva GCC, Bastos ID, Teixeira LA, Lustosa MA, Borda MCS, Couto SCR & Vicente TA. Dor. Rev. SBPH v.10 n.1 Rio de Janeiro jun. 2007.
Brasil. Ministério da Saúde. Instituto Nacional de Câncer. Cuidados paliativos oncológicos: controle da dor, p. 21-27, Rio de Janeiro: INCA, 2001.
Brinkman D. Morphine as a treatment of cancer-induced pain-is it safe? A review of in vivo studies and mechanisms. Naunyn Schmiedebergs Arch Pharmacol. 2018 Nov;391(11):1169-1178.
Cella IF et al. Prevalence of opiophobia in cancer pain treatment. Revista Dor [online]. 2016, v. 17, n. 4, pp. 245-247.
Choi HR, Song IA & Oh TK. Association of Opioid Use in the Week Before Death Among Patients with Advanced Lung Cancer Having Sepsis. Cancer Control. 2019 Jan-Dec;26(1).
Choudhary N, Singh S, Rathore P, Ambekar A & Bhatnagar S. Opioid Use Disorders among Patients on Long-Term Morphine for Management of Chronic Cancer Pain: A Pilot Study from a Tertiary Palliative Care Facility. Indian J Palliat Care. 2021 Apr-Jun;27(2):264-268.
Costa AGS, Rates MLS &Azevedo VMS. Risk of opioid abuse in non-oncologic chronic pain outpatient clinic. BrJP, 2021; 4(3).
Droney JM, Gretton SK, Sato H, Ross JR, Branford R, Welsh KI, Cookson W & Riley J. Analgesia and central side-effects: two separate dimensions of morphine response. Br J Clin Pharmacol. 2013 May;75(5):1340-50
Ertaş IE, Sehirali S, Ozsezgin Ocek S, Sancı M, Arbak G & Yıldırım Y. The effectiveness of subcutaneously implanted epidural ports for relief of severe pain in patients with advanced-stage gynecological cancer: a prospective study. Agri. 2014;26(1):8-14.
Kraychete DC, Gozzani JL & Kraychete, A. C. Dor neuropática: aspectos neuroquímicos. Revista Brasileira De Anestesiologia, 58. Rev. Bras. Anestesiol., 2008 58(5), 492–505.
Lee CW, Muo CH, Liang JA, Sung FC & Kao CH. Association of intensive morphine treatment and increased stroke incidence in prostate cancer patients: a population-based nested case–control study. Jpn J Clin Oncol. 2013 Aug;43(8):776-81
Lee CW, Muo CH, Liang JA, Lin MC & Kao CH. Atrial Fibrillation is Associated with Morphine Treatment in Female Breast Cancer Patients: A Retrospective Population-Based Time-Dependent Cohort Study. Medicine (Baltimore). 2016;95(11): e3102
Leppert W & Nosek K. Comparison of the Quality of Life of Cancer Patients with Pain Treated with Oral Controlled-Release Morphine and Oxycodone and Transdermal Buprenorphine and Fentanyl. Curr Pharm Des. 2019;25(30):3216-3224.
Matsuoka H, Tsurutani J, Chiba Y, Fujita Y, Sakai K, Yoshida T, Nakura M, Sakamoto R, Makimura C, Ohtake Y, Tanaka K, Hayashi H, Takeda M, Okuno T, Takegawa N, Haratani K, Koyama A, Nishio K & Nakagawa K. Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study). Oncologist. 2023, 17;28(3):278-e166.
Mendes TR et al. Ocorrência da dor nos pacientes oncológicos em cuidado paliativo. Acta Paulista de Enfermagem, 2014; 356-361.
Oosten AW, Abrantes JA, Jönsson S, Matic M, van Schaik RHN, de Bruijn P, van der Rijt CCD & Mathijssen RHJ. A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients. Clin Pharmacokinet. 2017;56(7):733-746
Onofre S & Alexandra F. Estudio comparativo sobre Coadyuvancia de Ketamina más Morfina versus Morfina en tratamiento de Dolor Oncológico / Comparative study on the Coadjuvancy of Ketamine plus Morphine versus Morphine in Cancer Pain. Rev. Oncol. Ecu. 2020:30(3).
Piovezan M et al. Opioid consumption and prescription in Brazil: integrative review. BrJP, 2022, 5(4)
Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H & Gibson S. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;23. Online ahead of print.
Riley J, Branford R, Droney J, Gretton S, Sato H, Kennett A, Oyebode C, Thick M, Wells A, Williams J, Welsh K & Ross J. Morphine, or oxycodone for cancer-related pain? A randomized, open-label, controlled trial. J Pain Symptom Manage. 2015;49(2):161-72.
Scarpi E, Calistri D, Klepstad P, Kaasa S, Skorpen F, Habberstad R, Nanni O, Amadori D & Maltoni M. Clinical and genetic factors related to cancer-induced bone pain and bone pain relief. Oncologist. 2014;19(12):1276-83.
Silva LJ, Mendanha DM & Gomes PP. The use of opioids in the treatment of oncologic pain in the elderly. BrJP. 2020, 3(1)
Zecca E, Brunelli C, De Sangro C, Bortolussi R, Moro C, Colonna U, Finco G, Roy MT, Ferrari V, Alabiso O, Rosti G, Kaasa Sn& Caraceni A. Comparison of the Tolerability Profile of Controlled-Release Oral Morphine and Oxycodone for Cancer Pain Treatment. An Open-Label Randomized Controlled Trial. J Pain Symptom Manage. 2016.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Nayanne Arero Pereira Melo, Rayanne Arero Pereira Melo, Beatriz Gomes de Sousa, Karen Mariane Santos Sousa, Keila Miranda Portilho, Matheus Vieira das Neves, Davi de Mendonça Viana, Isabela Guerreiro Diniz, Márcia Cristina Monteiro Guimarães